Sanofi

YTD

ALL

Why Robinhood?

You can watch Sanofi and buy or sell other stocks, ETFs, and their options commission-free!

About SNY

Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the Biopharma segment, which comprises commercial operations and research, development and production activities relating to the specialty care, general medicines and vaccines franchises plus support and corporate functions, for all geographical territories.

CEO

Olivier Antoine M. Charmeil

CEOOlivier Antoine M. Charmeil

Employees

76,493

Employees76,493

Headquarters

Paris, Ile-de-France

HeadquartersParis, Ile-de-France

Founded

1994

Founded1994

Employees

76,493

Employees76,493

SNY Key Statistics

Market cap

116.37B

Market cap116.37B

Price-Earnings ratio

19.66

Price-Earnings ratio19.66

Dividend yield

3.38%

Dividend yield3.38%

Average volume

5.36M

Average volume5.36M

High today

$47.73

High today$47.73

Low today

$47.01

Low today$47.01

Open price

$47.65

Open price$47.65

Volume

2.49M

Volume2.49M

52 Week high

$60.12

52 Week high$60.12

52 Week low

$44.62

52 Week low$44.62

SNY News

The Motley Fool 13h

Recursion Q4 2025 Earnings Call Transcript

Image source: The Motley Fool. Wednesday, Feb. 25, 2026 at 8 a.m. ET CALL PARTICIPANTS Chief Executive Officer — Najat Khan Chief Financial Officer — Ben Taylo...

Nasdaq 1d

FDA Approves Sanofi And Regeneron's Dupixent As First Medicine For Allergic Fungal Rhinosinusitis

(RTTNews) - Sanofi (SNY, SAN.PA) said FDA has approved Dupixent or dupilumab for the treatment of adult and pediatric patients aged 6 years and older with aller...

TipRanks 2d

Sanofi’s New Pediatric Fitusiran Trial Signals a Long-Term Hemophilia Push

Sanofi SA (SNY) announced an update on their ongoing clinical study. Sanofi Expands Pediatric Hemophilia Bet With New Fitusiran Phase 3 Study The study called...

Analyst ratings

67%

of 6 ratings

Buy

66.7%

Hold

33.3%

Sell

More SNY News

TipRanks 2d

Regeneron, Sanofi announce FDA approval of Dupixent for AFRS

Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) announced that the U.S. Food and Drug Administration has approved Dupixent for the treatment of adult and pedi...

TipRanks 3d

Sanofi Real-World Data Show Durable Two-Season Protection From Beyfortus in Infants

Sanofi ( (SNY) ) just unveiled an announcement. In February 2026, Sanofi highlighted new real-world data on its RSV antibody Beyfortus, showing strong performa...

TipRanks 6d

Sanofi price target lowered to EUR 80 from EUR 85 at Citi

Citi lowered the firm’s price target on Sanofi (SNY) to EUR 80 from EUR 85 and keeps a Neutral rating on the shares. Published first on TheFly – the ultimate s...

Simply Wall St 7d

Teva And Sanofi Duvakitug Data Support IBD Pipeline And Growth Story

Teva Pharmaceutical Industries (NYSE:TEVA) and Sanofi reported long term phase II extension data for duvakitug in ulcerative colitis and Crohn’s disease. The R...

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.